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We reported that connexin genes, a member of gap
junction, act as a tumor suppressor with certain specific- Calcium on trial:
ity [2, 3]. That is, connexin preferentially exerts a tumor-
suppressive effect on the tumor different from normal Beyond a reasonable doubt?
progenitor cells in which the particular connexin gene is
naturally expressed. Thus, to clarify the exact role of the
To the Editor: The interesting paper by Chertow et alconnexin gene as a tumor-suppressor gene in each tissue,
[1] brings up five interesting points. First, their studyit is necessary to determine the connexin subtype spe-
does not discuss previous studies with electron beamcifically expressed in the progenitor cell of each tumor.
tomography (EBT) in dialysis patients [2, 3], which dem-Recently, we showed that connexin 32 is specifically
onstrate different progression rates associated with lipiddown-regulated in renal cell carcinoma from mainte-
status [3], like that in the general population (Fig. 1),nance hemodialysis patients and several renal carcinoma
cells established from the maintenance hemodialysi pa- and show a lack of any relationship between serum cal-
tients [4]. On the other hand, we confirmed that human cium and EBT score in the general population [4].
renal proximal tubular cell (a progenitor cell of renal Second, the patients cited in Tables 3 and 4 of their
cell carcinoma) and noncancerous regions of kidneys study are not the same. Because Chertow et al excluded
from maintenance hemodialysis patients have the ex- patients with an EBT score30, evidence must be gath-
pression of connexin 32. Furthermore, we found that the ered to establish that the characteristics of the overall
recovery of the expression of connexin 32 in the renal population (92 who were given sevelamer and 94 who
carcinoma cells reduced some malignant phenotypes of were given calcium) are the same of the only 66 and 75
the cells. These results suggest that connexin 32 acts as patients, respectively, in whom the EBT scores have
a tumor suppressor against renal cell carcinoma from been evaluated.
mainenance hemodialysis patients. Overall, maintaining Third, those patients who progress rapidly have signifi-
the expression of connexin 32 during the development cantly higher mean serum calcium and rate of hypercalce-
of renal cell carcinoma in maintenance hemodialysis pa- mia (16% calcium subjects versus 5% sevelamer subjects)
tients may be a preventive procedure for the occurrence and at least one hypercalcemic episode (results, 43% and
of renal cell carcinoma.
17%, respectively). However, multivariate analysis evalu-
ating the role of hypercalcemia and hypercalcemic epi-Tomohiro Yano, Fumio Ito, Haruna Satoh,
Kiyokau Hagiwara, Hayakazu Nakazawa, sodes in the progression of calcification was lacking.
Hiroshi Toma, and Hiroshi Yamasaki Fourth, because only a minority of patients without
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coronary or aortic calcification progressed (five of 25 and
five of 32 patients), how many non-progressors belonged
to the sevelamer- or calcium-treated subgroups? Because 2003 by the International Society of Nephrology
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To the Editor: Although the study by Chertow et al
has shown that in hemodialysis patients, sevelamer com-
pared to calcium-based phosphate binders is less likely
to cause hypercalcemia and arterial calcifications, we do
not think that in the patients of this study sevelamer
should replace CaCO3. Indeed, their mild hyperparathy-
roidism could have been corrected by just higher doses
Fig. 1. Progression of calcium score as measured by electron beam of CaCO3 alone without aluminum hydroxide [Al (OH)3]tomography in coronaric artery in people with different lipid status.
or calcitriol. In fact, a high dose of CaCO3, without theFaster progression was associated with high lipids in all studies (at least
10 months of follow-up). Callister (N Engl J Med 339:1972, 1998, cited by co-administration of calcitrol, offers the distinct advan-
Chertow, Burke, and Raggi) reported a 52% rate of progression in pa- tage of maintaining lower serum-phosphate concentra-tients with coronary artery disease left untreated versus 25% in patients
treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re- tion without higher serum calcium [1]. This is probably
ductase inhibitors and low-density lipoprotein (LDL) cholesterol. Bu- due to the fact that calcitriol increases intestinal absorp-
doff (Am J Cardiol 86:8, 2000) reported 39% versus 15% in the presence
tion of phosphate whereas CaCO3 decreases it.of statin therapy in asymptomatic subjects. Pohle (Circulation 104:1927,
2001) reported 39% in patients with aortic valve calcification versus 16% Therefore, to clinically justify the preferential use of
in those with low LDL. Tamashiro et al (Am J Kidney Dis 38:64–69, “sevelamer plus calcitriol” over that of CaCO3, the lower2001) reported a faster rate of progression in dialysis patients with high
risk of arterial calcification should have been demon-trygliceride and low high-density lipoprotein (HDL) cholesterol (the
absolute number,432 458 versus7.5 31 are changed in percent- strated against higher doses of CaCO3 without calcitriolage in this figure to obtain an homogeneous picture)
while actually obtaining in both groups the same “tar-
geted” ranges for serum concentrations of parathyroid
hormone, calcium, and phosphate. The issue is indeed to
vascular calcification is an active process, did hyper- know whether despite comparable serum chemistry, the
calcemic patients also lack any progression? higher oral doses of calcium are actually increasing
Finally, since calcium and sevelamer patients should
the arterial calcium load more than calcitriol. However,
have different acid-base status, was there a relationship
the negative direct bone mineralization effect of calcitriolbetween serum bicarbonate and calcification progres-
shown in vitamin D-receptor knockout mice [2] does notsion? Evidence shows that, to prevent vasculopathy, it is
support this possibility.important to avoid hypercalcemia (not normal calcemia)
The second issue is to know whether prevention ofby perhaps lowering the acceptable high end calcium
arterial calcification will improve cardiovascular risk in-range in order to reduce the risk of unwanted escape in
dependently of the improvement of uremic dyslipidemia,addition to hyperphosphoremia, dyslipemia, alkalosis,
which promotes atherosclerosis and therefore intimaland other medial manifestations.
calcification. Indeed, the control of dyslipidemia with
Caterina Canavese, Daniela Bergamo, Hamido Dib, statin decreases cardiovascular morbid mortality in high-
Francesca Bermond, and Manuel Burdese risk patients [3] and is much cheaper than sevelamer asTorino, Italy
a cholesterol-lowering drug.
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